298 related articles for article (PubMed ID: 24685370)
21. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
22. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
Nashan B
Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
[TBL] [Abstract][Full Text] [Related]
23. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
24. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
Bachmann F; Glander P; Budde K; Bachmann C
J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitors and diabetes.
Vergès B; Cariou B
Diabetes Res Clin Pract; 2015 Nov; 110(2):101-8. PubMed ID: 26421362
[TBL] [Abstract][Full Text] [Related]
26. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
27. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
28. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Holdaas H; Potena L; Saliba F
Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328
[TBL] [Abstract][Full Text] [Related]
29. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
Pengel LH; Liu LQ; Morris PJ
Transpl Int; 2011 Dec; 24(12):1216-30. PubMed ID: 21955006
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus and everolimus in kidney transplantation.
Moes DJ; Guchelaar HJ; de Fijter JW
Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
[TBL] [Abstract][Full Text] [Related]
31. Adverse events associated with mTOR inhibitors.
Pallet N; Legendre C
Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
[TBL] [Abstract][Full Text] [Related]
32. The pros and the cons of mTOR inhibitors in kidney transplantation.
Ponticelli C
Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
[TBL] [Abstract][Full Text] [Related]
33. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
[TBL] [Abstract][Full Text] [Related]
34. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
Lebwohl D; Anak O; Sahmoud T; Klimovsky J; Elmroth I; Haas T; Posluszny J; Saletan S; Berg W
Ann N Y Acad Sci; 2013 Jul; 1291():14-32. PubMed ID: 23659703
[TBL] [Abstract][Full Text] [Related]
35. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
37. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B
Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575
[TBL] [Abstract][Full Text] [Related]
38. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
39. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
[TBL] [Abstract][Full Text] [Related]
40. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
